Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1992 4
1993 1
1999 1
2000 1
2001 3
2002 6
2003 10
2004 6
2005 3
2006 3
2007 4
2008 2
2009 6
2010 4
2011 4
2012 3
2013 2
2014 5
2015 8
2016 7
2017 9
2018 11
2019 4
2020 7
2021 4
2022 5
2023 8
2024 5
2025 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

134 results

Results by year

Filters applied: . Clear all
Page 1
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.
Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ, Huemer F, Losonczy G, Johnson ML, Nishio M, Reck M, Mok T, Lam S, Shames DS, Liu J, Ding B, Lopez-Chavez A, Kabbinavar F, Lin W, Sandler A, Liu SV; IMpower133 Study Group. Horn L, et al. N Engl J Med. 2018 Dec 6;379(23):2220-2229. doi: 10.1056/NEJMoa1809064. Epub 2018 Sep 25. N Engl J Med. 2018. PMID: 30280641 Clinical Trial.
Homeopathic Treatment as an Add-On Therapy May Improve Quality of Life and Prolong Survival in Patients with Non-Small Cell Lung Cancer: A Prospective, Randomized, Placebo-Controlled, Double-Blind, Three-Arm, Multicenter Study.
Frass M, Lechleitner P, Gründling C, Pirker C, Grasmuk-Siegl E, Domayer J, Hochmair M, Gaertner K, Duscheck C, Muchitsch I, Marosi C, Schumacher M, Zöchbauer-Müller S, Manchanda RK, Schrott A, Burghuber O. Frass M, et al. Among authors: pirker c. Oncologist. 2020 Dec;25(12):e1930-e1955. doi: 10.1002/onco.13548. Epub 2020 Nov 7. Oncologist. 2020. PMID: 33010094 Free PMC article. Clinical Trial.
Drug-induced blaschkitis.
Brinkmeier T, Herbst RA, Schaller J, Kuegler K, Pirker C, Beiteke U, Grosshans E, Frosch PJ. Brinkmeier T, et al. Among authors: pirker c. Acta Derm Venereol. 2004;84(4):314-5. doi: 10.1080/00015550410025282. Acta Derm Venereol. 2004. PMID: 15339081 Free article. No abstract available.
Albumin-targeted oxaliplatin(iv) prodrugs bearing STING agonists.
Dijkstra M, Gutmann M, Gradl M, Federa A, Jaunecker C, Breitenstein JV, Vician P, Pirker C, Valcanover D, Heffeter P, Keppler BK, Berger W, Kowol CR. Dijkstra M, et al. Among authors: pirker c. Inorg Chem Front. 2025 Apr 4;12(13):4284-4305. doi: 10.1039/d5qi00433k. eCollection 2025 Jun 24. Inorg Chem Front. 2025. PMID: 40191696 Free PMC article.
Dual specific STAT3/5 degraders effectively block acute myeloid leukemia and natural killer/T cell lymphoma.
Pölöske D, Sorger H, Schönbichler A, de Araujo ED, Neubauer HA, Orlova A, Timonen SH, Abdallah DI, Ianevski A, Kuusanmäki H, Surbek M, Heyes E, Eder T, Wagner C, Suske T, Metzelder ML, Bergmann M, Dahlhoff M, Grebien F, Fleck R, Pirker C, Berger W, Hadzijusufovic E, Sperr WR, Kenner L, Valent P, Aittokallio T, Herling M, Mustjoki S, Gunning PT, Moriggl R. Pölöske D, et al. Among authors: pirker c. Hemasphere. 2024 Nov 28;8(12):e70001. doi: 10.1002/hem3.70001. eCollection 2024 Dec. Hemasphere. 2024. PMID: 39619245 Free PMC article.
Alternative lengthening of telomere-based immortalization renders H3G34R-mutant diffuse hemispheric glioma hypersensitive to PARP inhibitor combination regimens.
Laemmerer A, Lehmann C, Mayr L, Bruckner K, Gabler L, Senfter D, Meyer P, Balber T, Pirker C, Jaunecker CN, Kirchhofer D, Vician P, Griesser M, Spiegl-Kreinecker S, Schmook MT, Traub-Weidinger T, Kuess P, Eckert F, Federico A, Madlener S, Stepien N, Robl B, Baumgartner A, Hainfellner JA, Dieckmann K, Dorfer C, Roessler K, Corsini NS, Holzmann K, Schmidt WM, Peyrl A, Azizi AA, Haberler C, Beck A, Pfister SM, Schueler J, Lötsch-Gojo D, Knoblich JA, Berger W, Gojo J. Laemmerer A, et al. Among authors: pirker c. Neuro Oncol. 2025 Mar 7;27(3):811-827. doi: 10.1093/neuonc/noae228. Neuro Oncol. 2025. PMID: 39556024 Free PMC article.
Metal Drugs and the Anticancer Immune Response.
Englinger B, Pirker C, Heffeter P, Terenzi A, Kowol CR, Keppler BK, Berger W. Englinger B, et al. Among authors: pirker c. Chem Rev. 2019 Jan 23;119(2):1519-1624. doi: 10.1021/acs.chemrev.8b00396. Epub 2018 Nov 29. Chem Rev. 2019. PMID: 30489072 Review.
The tyrosine kinase inhibitor Nintedanib induces lysosomal dysfunctionality: Role of protonation-dependent crystallization processes.
Mosca E, Federa A, Pirker C, Schosserer M, Liendl L, Eckhard M, Sombke A, Dömötör O, Kirchhofer D, Timelthaler G, Baier D, Gurschka P, Gabler L, Reithofer M, Chin JM, Elsayad K, Englinger B, Tahir A, Kowol CR, Berger W. Mosca E, et al. Among authors: pirker c. Chem Biol Interact. 2024 Nov 1;403:111243. doi: 10.1016/j.cbi.2024.111243. Epub 2024 Sep 14. Chem Biol Interact. 2024. PMID: 39284504 Free article.
Anticancer metal drugs and immunogenic cell death.
Terenzi A, Pirker C, Keppler BK, Berger W. Terenzi A, et al. Among authors: pirker c. J Inorg Biochem. 2016 Dec;165:71-79. doi: 10.1016/j.jinorgbio.2016.06.021. Epub 2016 Jun 16. J Inorg Biochem. 2016. PMID: 27350082 Review.
134 results